These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 209810)

  • 1. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial clinical experience with the radiosensitizing nitroimidazole Ro 07-0582.
    Jentzsch K; Kärcher KH; Kogelnik HD; Maida E; Mamoli B; Wessely P; Zaunbauer F; Nitsche V
    Strahlentherapie; 1977 Dec; 153(12):825-31. PubMed ID: 601838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypoxic cell sensitizer programme in the United States.
    Phillips TL; Wasserman TH; JohnsonRJ ; Gomer CJ; Lawrence GA; Levine ML; Sadee W; Penta JS; Rubin DJ
    Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
    Palcic B; Faddegon B; Skarsgard LD
    Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged metronidazole administration with protracted radiotherapy: a pilot study on response of advanced tumours.
    Karim AB
    Br J Cancer Suppl; 1978 Jun; 3():299-301. PubMed ID: 277249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
    Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821
    [No Abstract]   [Full Text] [Related]  

  • 16. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
    Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.
    Ohizumi Y; Murayama C; Maezawa H; Mori T
    Tokai J Exp Clin Med; 1984 Oct; 9(4):331-7. PubMed ID: 6537042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The demonstration of in vivo misonidazole tumour toxicity using post radiation hypoxia.
    Gomer CJ; Johnson RJ; Hetzel FW; Lawrence G
    Br J Cancer Suppl; 1978 Jun; 3():228-31. PubMed ID: 277234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer].
    Murayama C; Mori T
    Gan No Rinsho; 1990 Oct; 36(13):2249-54. PubMed ID: 2147449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.